# A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

> clinical trial · VERIFIED · 2026-08-18

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Primary Myelofibrosis (PMF)

- Company: Novartis Pharmaceuticals
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT07357727

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.